Mirdametinib
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts[1][2][3].
Product Specifications
CAS Number
[391210-10-9]
Product Name Alternative
PD0325901; PD325901
UNSPSC
12352005
Hazard Statement
H301, H373, H413
Target
Apoptosis; Autophagy; MEK
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PD0325901.html
Purity
99.95
Solubility
DMSO : ≥ 56 mg/mL
Smiles
O=C(C1=CC=C(C(F)=C1NC2=CC=C(I)C=C2F)F)NOC[C@H](O)CO
Molecular Formula
C16H14F3IN2O4
Molecular Weight
482.19
Precautions
H301, H373, H413
References & Citations
[1]Barrett SD, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008 Dec 15;18 (24) :6501-4.|[2]Henderson YC, et al. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9 (7) :1968-76.|[3]Judith S. Sebolt-Leopold, et al. The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
MEK; MEK1; MEK2
Citation 01
Andrology. 2025 Jun 16.|Animals (Basel) . 2021 Feb 6;11 (2) :425.|Animals (Basel) . 2024 May 4;14 (9) :1382.|Biochem Biophys Res Commun. 2020 Apr 2;524 (2) :280-287.|Biochem Biophys Res Commun. 2022 Jan 29:590:125-131.|Biochem Biophys Res Commun. 2023 Jan 29:642:145-153.|Biol Reprod. 2024 May 9;110 (5) :950-970.|Biomaterials. 2018 Oct;180:12-23.|Bioorg Chem. 2023 Mar:132:106321.|Bioorg Med Chem. 2023 Jul 15:90:117366.|bioRxiv. 2019 Sep.|bioRxiv. 2023 Aug 14.|bioRxiv. 2023 Jun 15:2023.06.15.545148.|bioRxiv. 2024 Apr 2.|bioRxiv. 2024 Aug 31:2024.08.29.610385.|bioRxiv. 2024 Dec 10:2024.12.09.627542.|bioRxiv. 2024 Dec 6:2024.12.06.627179.|bioRxiv. 2024 Feb 27.|bioRxiv. 2024 Mar 12.|bioRxiv. 2025 Feb 2:2025.02.01.636075.|bioRxiv. 2025 January 18.|bioRxiv. 2025 January 28.|bioRxiv. 2025 March 21.|bioRxiv. 2025 Nov 20:2025.11.20.689490.|bioRxiv. 2025 Oct 14.|bioRxiv. 2025 Oct 17.|bioRxiv. 2025 Sep 5.|Blood Adv. 2023 Jul 11;7 (13) :3199-3212.|Brain Res Bull. 2019 Oct:152:285-296.|Cancer Cell Int. 2021 Jun 5;21 (1) :291.|Cancer Lett. 2019 Feb 1:442:202-212.|Cancers (Basel) . 2022 Oct 31;14 (21) :5368.|Cell Death Dis. 2021 Oct 30;12 (11) :1034.|Cell Death Dis. 2022 Mar 30;13 (3) :284.|Cell Death Discov. 2021 Oct 2;7 (1) :271.|Cell Prolif. 2022 Apr;55 (4) :e13209.|Cell Prolif. 2023 Dec;56 (12) :e13498.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2022 Mar 29;38 (13) :110570.|Cell Rep. 2025 Mar 5;44 (3) :115362.|Cell Stem Cell. 2022 Jul 7;29 (7) :1102-1118.e8.|Cell Stem Cell. 2025 Aug 29;32 (10) :1509-1527.e9|Cell Stem Cell. 2025 Mar 6;32 (3) :409-425.e8.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell Syst. 2020 Nov 18;11 (5) :478-494.e9.|Cell. 2024 Nov 14;187 (23) :6566-6583.e22.|Cell. 2025 Oct 30;188 (22) :6301-6316.e29.|Chem Biol. 2012 Jan 27;19 (1) :140-54.|Chem Eng J. 2024 Sep 1.|Clin Cancer Res. 2014 Nov 1;20 (21) :5483-95. |Clin Cancer Res. 2020 Apr 15;26 (8) :2011-2021. |Comput Biol Med. 2025 Jul 5;196 (Pt A) :110721.|Curr Protoc Cell Biol. 2018 Dec;81 (1) :e62.|Dev Cell. 2025 Jul 21;60 (14) :2007-2022.e7.|EMBO Rep. 2022 Feb 3;23 (3) :e53191.|Environ Int. 2025 Sep 28:204:109820.|Epilepsy Res. 2022 Mar:181:106890.|Eur J Pharm Sci. 2021 Dec 1:167:106003.|Exp Cell Res. 2023 Jun 15;427 (2) :113603.|FEBS Open Bio. 2021 Oct;11 (10) :2740-2755.|FEBS Open Bio. 2025 Sep 10.|Front Cell Dev Biol. 2018 Sep 25:6:111.|Front Neurosci. 2022 Jun 7;16:901688.|Fundam Clin Pharmacol. 2020 Oct;34 (5) :571-580.|Gene. 2025 Jan 15:933:148985.|Genes (Basel) . 2024 Oct 30;15 (11) :1400.|Genome Biol. 2025 Jul 7;26 (1) :196.|Glia. 2019 Jul;67 (7) :1320-1332. |Harvard Medical School LINCS LIBRARY|Int Immunopharmacol. 2021 Apr:93:107395.|Int J Mol Sci. 2024 Sep 21;25 (18) :10138.|Int J Mol Sci. 2025 Jun 16;26 (12) :5758.|iScience. 2023 Jul 26;26 (8) :107469.|J Anim Sci. 2024 Jan 3:102:skae251.|J Biol Chem. 2012 Mar 23;287 (13) :9742-52.|J Biol Chem. 2020 Oct 16;295 (42) :14325-14342.|J Exp Clin Cancer Res. 2018 Feb 20;37 (1) :32. |J Exp Clin Cancer Res. 2018 Jun 28;37 (1) :128. |J Exp Clin Cancer Res. 2025 Nov 6;44 (1) :300.|J Hazard Mater. 2023 Oct 5:459:132225.|J Invest Dermatol. 2022 Mar;142 (3 Pt A) :613-623.e7.|JCI Insight. 2025 Sep 23;10 (18) :e190716.|Lung Cancer. 2025 Nov 19:211:108848.|Lwt-Food Sci Technol. 11 Oct 2021.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nat Commun. 2022 Nov 29;13 (1) :7345.|Nat Commun. 2024 Dec 12;15 (1) :10476.|Nat Commun. 2024 Sep 5;15 (1) :7758.|Nat Commun. 2025 Jul 1;16 (1) :5540.|Nat Commun. 2025 Mar 17;16 (1) :2635.|Nat Immunol. 2025 Oct;26 (10) :1673-1685.|Nat Methods. 2025 Mar;22 (3) :510-519.|Nat Protoc. 2023 May;18 (5) :1584-1620.|Nat Struct Mol Biol. 2025 Sep 1.|Nature. 2022 Jan;601 (7894) :600-605.|Nature. 2025 Jan;637 (8046) :726-735. |Neuro Oncol. 2019 Mar 18;21 (4) :486-497. |Neuroscience. 2024 May 9:S0306-4522 (24) 00196-9.|Nucleic Acids Res. 2021 Nov 18;49 (20) :11575-11595.|Oncotarget. 2020 Nov 3;11 (44) :3921-3932.|Patent. US20140309249A1.|Patent. US20160368910A1.|Patent. US20180263995A1.|Patent. US20190248778A1.|Patent. US20240307414A1.|PeerJ. 2020 Oct 2;8:e9981.|Platelets. 2022 Jul 4;33 (5) :755-763.|Preprints. 2023 May 5.|Proc Natl Acad Sci U S A. 2019 Jun 18;116 (25) :12147-12152.|Redox Biol. 2025 Apr:81:103539.|Research Square Preprint. 2022 Feb.|Research Square Print. October 21st, 2022.|Sci China Life Sci. 2025 Jul;68 (7) :2058-2072.|Sci Data. 2024 Sep 19;11 (1) :1024.|Sci Rep. 2025 Nov 17;15 (1) :40227.|Sci Signal. 2021 Jun 22;14 (688) :eabe6156.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Signal Transduct Target Ther. 2024 Mar 9;9 (1) :65.|SSRN. 2023 Sep 1.|SSRN. 2025 Apr 24.|SSRN. 2025 May 27.|STAR Protoc. 2021 Nov 5;2 (4) :100881.|STAR Protoc. 2023 Feb 3;4 (1) :102092.|STAR Protoc. 2023 Mar 16;4 (2) :102151.|Stem Cell Reports. 2025 Jan 23:102398.|Stem Cell Res Ther. 2024 Dec 18;15 (1) :473.|Stem Cell Res Ther. 2025 Oct 8;16 (1) :547.|Stem Cells Int. 2018 Dec 25:2018:5965727.|Stem Cells Int. 2020 Feb 3;2020:8483035.|Stem Cells Transl Med. 2021 May;10 (5) :743-755.|Stem Cells. 2022 Oct 21;40 (10) :892-905.|Toxicon. 2026 Jan:269:108660.|Transl Oncol. 2023 Mar:29:101628.|Universidad Del Pais Vasco. 2023 Jun 22.|Virology. 2020 Jan 2;539:121-128.|Viruses. 2018 Apr 13;10 (4) . pii: E191.|bioRxiv. 2025 Nov 12.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
